HOME > TOP STORIES

TOP STORIES

REGULATORY PFSB Draft Budget Includes ¥2.1 Bil. to Improve Review, Safety Measures

December 27, 2011
BUSINESS Chugai to Participate in Multinational Study of Avastin in Breast Cancer

December 27, 2011
REGULATORY Tougher Restrictions on Reimbursement of Vitamins to Cut ¥15 Bil. from Med. Expenditure

December 26, 2011
REGULATORY ¥25 Bil. to Be Saved through Add’l NHI Price Cuts for Both Long-listed, Generic Drugs in FY2012: MHLW

December 26, 2011
REGULATORY 0.9% Additional Price Cut for Long-Listed Drugs, Compensating Upward Revision of Nursing Fee: Minister Negotiation

December 22, 2011
BUSINESS Ranbaxy Settles with US FDA, Commits to Improvements in GMP Compliance, Data Integrity: Daiichi Sankyo

December 22, 2011
REGULATORY CSIMC Approves Additional Price Reduction for Long-listed Drugs Next Year

December 22, 2011
REGULATORY Price Cut Negotiations for Long-Listed Products Between MOF, Health Ministers “Parallel”

December 21, 2011
BUSINESS MTPC, Novartis Pharma Focused on Promoting Proper Use of MS Treatment Imusera/Gilenya

December 21, 2011
BUSINESS Chugai to Establish Pool System of Candidate Leaders

December 20, 2011
ORGANIZATION Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics

December 20, 2011
REGULATORY MHLW Subcommittee Agrees on Mandatory Notification of Package Inserts

December 19, 2011
REGULATORY Expert Subcommittee Agrees to 2-Year Continuation of Trial of Premium for New Drug Development

December 19, 2011
BUSINESS ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April

December 16, 2011
REGULATORY Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery

December 15, 2011
ORGANIZATION Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development

December 15, 2011
REGULATORY CSIMC Approves Draft Measures to Promote Generic Drug Use

December 15, 2011
BUSINESS MTPC to Focus on Development of Global Human Resources

December 14, 2011
ORGANIZATION Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report

December 14, 2011
BUSINESS Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision

December 13, 2011

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…